BCRX,CLSD Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Dollar change +0.11
Percentage change 1.43	%

Peers: VRTX REGN IONS ALNY SRPT PTCT BMRN CRSP BLUE RARE

| Held by: VTI IWM XBI VXF VB IWO VBK IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	5.32%	Shs Outstand	205.77M	Perf Week	-7.71%
Market Cap	1.63B	Forward P/E	-	EPS next Y	-0.07	Insider Trans	1.49%	Shs Float	196.10M	Perf Month	9.27%
Income	-123.82M	PEG	-	EPS next Q	-0.08	Inst Own	83.49%	Short Float	11.49%	Perf Quarter	0.65%
Sales	412.58M	P/S	3.96	EPS this Y	68.05%	Inst Trans	0.39%	Short Ratio	11.45	Perf Half Y	46.24%
Book/sh	-2.26	P/B	-	EPS next Y	80.37%	ROA	-24.42%	Short Interest	22.53M	Perf Year	42.23%
Cash/sh	1.57	P/C	4.94	EPS next 5Y	44.80%	ROE	-	52W Range	4.03 - 8.88	Perf YTD	29.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-3.73%	ROI	-36.67%	52W High	-12.39%	Beta	1.81
Dividend TTM	-	Quick Ratio	2.73	Sales past 5Y	190.00%	Gross Margin	97.73%	52W Low	93.05%	ATR (14)	0.41
Dividend Ex-Date	-	Current Ratio	2.78	EPS Y/Y TTM	51.59%	Oper. Margin	-9.87%	RSI (14)	50.38	Volatility	8.08% 4.97%
Employees	536	Debt/Eq	-	Sales Y/Y TTM	29.92%	Profit Margin	-30.01%	Recom	1.20	Target Price	15.10
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	64.43%	Payout	-	Rel Volume	0.80	Prev Close	7.67
Sales Surprise	2.71%	EPS Surprise	-1.60%	Sales Q/Q	34.98%	Earnings	Nov 04 BMO	Avg Volume	1.97M	Price	7.78
SMA20	-0.22%	SMA50	0.24%	SMA200	20.20%	Trades		Volume	1,573,103	Change	1.43%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Overweight	$10
Sep-18-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$9 → $10
Aug-04-23	Upgrade	Jefferies	Hold → Buy	$11
Jul-13-23	Upgrade	BofA Securities	Neutral → Buy	$10
Feb-22-23	Upgrade	Needham	Hold → Buy	$14
Nov-02-22	Upgrade	Evercore ISI	In-line → Outperform	$14 → $16
Aug-05-22	Downgrade	Oppenheimer	Outperform → Perform
Aug-05-22	Downgrade	Evercore ISI	Outperform → In-line	$14
Apr-18-22	Downgrade	Barclays	Overweight → Equal Weight	$22 → $13
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $14
Dec-10-21	Initiated	Oppenheimer	Outperform	$16
Aug-06-21	Downgrade	Jefferies	Buy → Hold
Aug-03-21	Initiated	Cantor Fitzgerald	Overweight	$21
Mar-01-21	Initiated	Cowen	Outperform	$16
Sep-29-20	Resumed	JP Morgan	Overweight	$7
Jun-17-20	Initiated	BTIG Research	Neutral
May-05-20	Upgrade	Barclays	Equal Weight → Overweight	$7
Nov-15-19	Upgrade	BofA/Merrill	Neutral → Buy	$5 → $4
May-24-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16 → $4.50
Nov-16-18	Resumed	Piper Jaffray	Overweight	$15

Show Previous Ratings

Nov-06-24 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire) +9.57%
Nov-05-24 07:29AM	BioCryst Announces Strong Q3 2024 Revenue Growth (TipRanks)
07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:32AM	Q3 2024 BioCryst Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:03AM	BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ... (GuruFocus.com)
02:30PM	Loading…
Nov-04-24 02:30PM	BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript (Motley Fool) -12.81%
08:10AM	BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:06AM	BioCryst: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-24-24 08:00AM	BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO (berotralstat) (GlobeNewswire)
Oct-23-24 09:55AM	How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5% (Zacks)
Oct-21-24 07:00AM	BioCryst to Report Third Quarter 2024 Financial Results on November 4 (GlobeNewswire)
Oct-17-24 03:05PM	State Street Corp's Strategic Reduction in BioCryst Pharmaceuticals Holdings (GuruFocus.com)
Oct-14-24 07:00AM	BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO (berotralstat) (GlobeNewswire)
Oct-11-24 12:15PM	Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler? (Insider Monkey)
07:00AM	Loading…
Oct-10-24 07:00AM	BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-09-24 08:03AM	BioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2 (Insider Monkey)
Oct-07-24 12:00PM	BioCryst (BCRX) Upgraded to Buy: Here's Why (Zacks)
Oct-03-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-24 07:00AM	BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome (GlobeNewswire)
Oct-01-24 07:30AM	BioCryst Secures Major US Health Department Influenza Drug Deal (TipRanks)
06:53AM	BioCryst secures $69m contract from US to supply RAPIVAB for influenza (Pharmaceutical Technology)
Sep-30-24 07:00AM	U.S. Government Awards BioCryst $69 Million RAPIVAB (peramivir injection) Contract for Strategic National Stockpile (GlobeNewswire)
Sep-17-24 07:00AM	BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks (GlobeNewswire)
Sep-12-24 01:25AM	BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals (GuruFocus.com)
Sep-06-24 02:00AM	BioCryst Presents New ORLADEYO (berotralstat) Data at 7th Bradykinin Symposium (GlobeNewswire)
Sep-05-24 07:00AM	BioCryst Appoints Dr. Donald Fong Chief Medical Officer (GlobeNewswire)
Sep-04-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-22-24 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-06-24 08:45AM	Rapid Advancements of Innovative Antiviral COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market (GlobeNewswire)
01:00PM	Loading…
Aug-05-24 01:00PM	BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript (Motley Fool) +6.98%
09:55AM	Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect? (Zacks)
08:10AM	BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:06AM	BioCryst: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-02-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-30-24 12:25PM	7 Small-Cap Stocks to Buy for Large-Scale Gains (InvestorPlace)
Jul-29-24 10:00AM	Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-22-24 07:00AM	BioCryst to Report Second Quarter 2024 Financial Results on August 5 (GlobeNewswire)
Jul-18-24 12:00PM	BioCryst (BCRX) Upgraded to Strong Buy: Here's Why (Zacks)
09:55AM	Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High? (Zacks)
Jul-10-24 04:32AM	ORLADEYO gains approval in Peru for HAE prevention (Pharmaceutical Technology)
Jul-09-24 07:00AM	ORLADEYO (berotralstat) Approved in Peru (GlobeNewswire)
Jul-02-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-24 04:00AM	BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO (berotralstat) Treatment (GlobeNewswire)
May-15-24 01:13PM	BioCryst Pharmaceuticals Shares Rise 20% Following Disclosure of Executive Share Purchases (MT Newswires) +18.66%
11:00AM	Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst ... (GuruFocus.com)
11:00AM	Director Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX) (GuruFocus.com)
11:00AM	Insider Buying: Charles Gayer Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) (GuruFocus.com)
11:00AM	Insider Buying: CFO Anthony Doyle Acquires Shares of BioCryst Pharmaceuticals Inc (BCRX) (GuruFocus.com)
May-14-24 07:00AM	BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology (GlobeNewswire)
May-13-24 10:31AM	BioCryst Says Orladeyo Granted Approval in Mexico (MT Newswires) +5.83%
07:00AM	ORLADEYO (berotralstat) Approved in Mexico (GlobeNewswire)
May-09-24 07:00AM	BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO (berotralstat) (GlobeNewswire)
May-07-24 11:51AM	JMP Securities Adjusts Price Target on BioCryst Pharmaceuticals to $15 From $14, Maintains Market Outperform Rating (MT Newswires)
10:50AM	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
03:01AM	BioCryst Pharmaceuticals Inc (BCRX) Q1 2024 Earnings Call Transcript Highlights: Key Financial ... (GuruFocus.com)
01:13AM	Q1 2024 BioCryst Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-06-24 06:47PM	Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday (Motley Fool) +18.43%
04:59PM	BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance (Benzinga)
01:00PM	BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript (Motley Fool)
12:35PM	BioCryst Pharmaceuticals, Freshpet rise; Luminar, Integra fall, Tuesday, 5/6/2024 (Associated Press)
12:35PM	BioCryst Pharmaceuticals, Freshpet rise; Luminar, Integra fall, Monday, 5/6/2024 (Associated Press Finance)
11:53AM	BCRX Stock Earnings: BioCryst Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
11:45AM	BioCryst Pharmaceuticals Shares Jump After Q1 Beat (MT Newswires)
08:32AM	BioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue Forecasts (GuruFocus.com)
08:10AM	BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:10AM	BioCryst: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-03-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-29-24 10:00AM	BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-22-24 07:00AM	BioCryst to Report First Quarter 2024 Financial Results on May 6 (GlobeNewswire)
Apr-17-24 05:14AM	Orladeyo gains approval in Brazil for HAE prevention (Pharmaceutical Business Review)
04:30AM	BioCryst Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency (GlobeNewswire)
Apr-10-24 06:09PM	12 Best Depressed Stocks To Buy in 2024 (Insider Monkey)
Apr-03-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-25-24 04:01PM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-05-24 07:01AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-24 08:29AM	Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects (InvestorPlace)
Feb-28-24 10:47AM	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:05AM	Q4 2023 BioCryst Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-24 04:45PM	BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript (Motley Fool)
08:10AM	BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:32AM	BioCryst Pharmaceuticals Inc (BCRX) Reports Growth in ORLADEYO Revenue and Projects ... (GuruFocus.com)
07:09AM	BioCryst: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones (GlobeNewswire)
Feb-23-24 07:00AM	BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO (berotralstat) Treatment (GlobeNewswire)
Feb-21-24 04:01PM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-19-24 07:54AM	BioCryst Launches ORLADEYO (berotralstat) in Italy (GlobeNewswire)
Feb-12-24 07:00AM	BioCryst to Report Fourth Quarter 2023 Financial Results on February 26 (GlobeNewswire)
Feb-05-24 07:00AM	BioCryst to Present New ORLADEYO (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (GlobeNewswire)
Feb-02-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-24 09:25AM	BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last? (Zacks)
Jan-05-24 04:01PM	BioCryst Announces Preliminary Full Year 2023 ORLADEYO (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability (GlobeNewswire) -5.73% +25.62%
Jan-03-24 04:01PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.67%
07:00AM	BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-23 07:00AM	BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO (berotralstat) (GlobeNewswire)

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McKee Amy E	Director	Jun 24 '24	Sale	6.32	8,600	54,352	27,831	Jun 25 04:39 PM
SANDERS MACHELLE	Director	Jun 17 '24	Sale	6.00	4,689	28,134	27,742	Jun 17 04:31 PM
HEGGIE THERESA	Director	Jun 14 '24	Sale	6.11	6,698	40,925	52,852	Jun 14 04:25 PM
LEVIN ALAN G	Director	May 30 '24	Buy	6.36	7,861	49,996	44,951	May 31 04:25 PM
ASELAGE STEVE	Director	May 24 '24	Buy	6.40	2,500	16,000	2,500	May 29 04:16 PM
Hutson Nancy J	Director	May 20 '24	Buy	6.38	5,000	31,900	86,818	May 22 07:24 AM
MILANO VINCENT	Director	May 20 '24	Buy	6.25	15,000	93,750	66,997	May 22 07:21 AM
Doyle Anthony	Chief Financial Officer	May 14 '24	Buy	5.57	36,300	202,191	266,744	May 15 07:19 AM
Thackray Helen M.	Chief R&D Officer	May 14 '24	Buy	5.86	30,000	175,800	272,139	May 15 07:17 AM
Galson Steven K	Director	May 13 '24	Buy	5.49	21,940	120,451	51,551	May 15 07:14 AM
Barnes Alane P	Chief Legal Officer	May 13 '24	Buy	5.53	5,000	27,650	300,762	May 15 07:11 AM
Stonehouse Jon P	President & CEO	May 13 '24	Buy	5.55	30,000	166,500	1,127,770	May 15 07:08 AM
Gayer Charles K	Chief Commercial Officer	May 13 '24	Buy	5.47	30,000	164,100	307,533	May 15 07:04 AM

Dollar change +0.03
Percentage change 2.70	%

CLSD Clearside Biomedical Inc daily Stock Chart

Peers: EYPT VKTX OCUL CARA ALDX RIGL IRD AKBA BYSI

| Held by: VTI VXF IWC EVNT

Index	-	P/E	-	EPS (ttm)	-0.50	Insider Own	15.41%	Shs Outstand	74.75M	Perf Week	12.87%
Market Cap	87.51M	Forward P/E	-	EPS next Y	-0.50	Insider Trans	0.58%	Shs Float	63.23M	Perf Month	-13.64%
Income	-33.46M	PEG	-	EPS next Q	-0.12	Inst Own	18.00%	Short Float	3.09%	Perf Quarter	6.54%
Sales	7.52M	P/S	11.64	EPS this Y	6.74%	Inst Trans	-20.88%	Short Ratio	2.67	Perf Half Y	-8.80%
Book/sh	-0.38	P/B	-	EPS next Y	-0.29%	ROA	-91.51%	Short Interest	1.95M	Perf Year	10.68%
Cash/sh	0.38	P/C	2.98	EPS next 5Y	-	ROE	-1310.02%	52W Range	0.76 - 2.12	Perf YTD	-2.56%
Dividend Est.	-	P/FCF	-	EPS past 5Y	27.88%	ROI	-176.65%	52W High	-46.23%	Beta	2.32
Dividend TTM	-	Quick Ratio	5.07	Sales past 5Y	1621.13%	Gross Margin	96.68%	52W Low	50.71%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	5.07	EPS Y/Y TTM	15.68%	Oper. Margin	-342.48%	RSI (14)	50.47	Volatility	4.35% 7.02%
Employees	30	Debt/Eq	-	Sales Y/Y TTM	365.02%	Profit Margin	-444.66%	Recom	1.00	Target Price	5.86
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	31.21%	Payout	-	Rel Volume	0.40	Prev Close	1.11
Sales Surprise	-28.85%	EPS Surprise	26.31%	Sales Q/Q	-91.16%	Earnings	Nov 12 AMC	Avg Volume	729.92K	Price	1.14
SMA20	2.66%	SMA50	-3.53%	SMA200	-9.97%	Trades		Volume	294,734	Change	2.70%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-21-24	Initiated	Chardan Capital Markets	Buy	$6
Jun-25-24	Initiated	Oppenheimer	Outperform	$5
Dec-15-21	Resumed	Wedbush	Outperform	$19 → $9
Jul-29-21	Initiated	H.C. Wainwright	Buy	$10
May-13-20	Initiated	ROTH Capital	Buy	$8
Aug-09-19	Downgrade	Needham	Buy → Hold
Nov-05-18	Downgrade	Stifel	Buy → Hold
Nov-05-18	Downgrade	JP Morgan	Overweight → Underweight
Nov-05-18	Downgrade	Cowen	Outperform → Market Perform
Mar-06-18	Reiterated	Needham	Buy	$18 → $22
May-25-17	Initiated	JMP Securities	Mkt Outperform	$21
Feb-24-17	Initiated	JP Morgan	Overweight	$19
Nov-10-16	Reiterated	Needham	Buy	$16 → $24
Oct-24-16	Reiterated	Stifel	Buy	$13 → $23

Show Previous Ratings

Nov-08-24 03:56AM	Santen, Arctic Vision sign deal for ARVN001 to treat UME (Pharmaceutical Technology)
Nov-07-24 09:05AM	Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema (GlobeNewswire)
Nov-06-24 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-04-24 07:05AM	Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors (GlobeNewswire)
Oct-31-24 07:05AM	Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 (GlobeNewswire)
07:05AM	Loading…
Oct-22-24 07:05AM	Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting (GlobeNewswire) -10.23%
Oct-10-24 08:57AM	Morning Movers: Arcadium Lithium surges after deal to be acquired (TipRanks)
Oct-09-24 10:22AM	Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study (Benzinga) -11.49%
06:30AM	Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes (GlobeNewswire)
Aug-27-24 07:05AM	Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD (GlobeNewswire)
Aug-15-24 09:35AM	After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD) (Zacks)
Aug-12-24 05:25PM	Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-24 07:05AM	Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-05-24 10:00AM	Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
07:05AM	Loading…
Aug-01-24 07:05AM	Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024 (GlobeNewswire)
Jul-29-24 04:05PM	Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS for Suprachoroidal Use in Uveitic Macular Edema Patients in China (GlobeNewswire)
Jul-22-24 12:00PM	Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET (GlobeNewswire)
Jul-11-24 07:05AM	Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board (GlobeNewswire)
Jun-27-24 07:05AM	Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery (GlobeNewswire) +5.79%
Jun-12-24 07:05AM	Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting (GlobeNewswire)
May-21-24 07:05AM	Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS ) Injection in Leading Peer-Reviewed Industry Journal, RETINA (GlobeNewswire) +12.03%
May-13-24 08:20AM	HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating (MT Newswires)
May-10-24 02:15PM	Q1 2024 Clearside Biomedical Inc Earnings Call (Thomson Reuters StreetEvents) -7.41%
11:56AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 06:55PM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +6.30%
04:05PM	Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 04:15PM	Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-30-24 07:05AM	Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 (GlobeNewswire)
Apr-16-24 07:05AM	Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors (GlobeNewswire) -10.85%
07:05AM	Loading…
Apr-02-24 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -11.39%
Mar-18-24 07:05AM	Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer (GlobeNewswire) -8.77%
Mar-13-24 08:30AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:38AM	Q4 2023 Clearside Biomedical Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 05:35PM	Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ... (GuruFocus.com) -18.81%
04:05PM	Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 02:25PM	These 2 Strong Buy Penny Stocks Could Surge Over 200%, Say Analysts (TipRanks) +8.63%
Feb-29-24 07:05AM	Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024 (GlobeNewswire)
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-07-24 08:00AM	Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering (GlobeNewswire)
Dec-14-23 07:05AM	Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD (GlobeNewswire)
Nov-14-23 09:11AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 04:05PM	Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-08-23 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference (GlobeNewswire) -9.65%
Nov-07-23 04:20PM	Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting (GlobeNewswire)
Nov-03-23 12:00PM	BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector (GlobeNewswire) +19.39%
Nov-02-23 07:05AM	Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting (GlobeNewswire)
Nov-01-23 07:05AM	Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD (GlobeNewswire) +5.30%
Oct-31-23 07:05AM	Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023 (GlobeNewswire) +5.17%
Oct-26-23 12:24AM	3 Cheap Stocks to Buy Under $1 in October 2023 (InvestorPlace) -5.28%
Oct-16-23 07:05AM	Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting (GlobeNewswire)
Oct-04-23 09:00AM	Clearside Biomedical Announces Advancement of XIPERE in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China (GlobeNewswire)
Oct-03-23 04:35PM	Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit (GlobeNewswire)
Sep-19-23 07:05AM	Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference (GlobeNewswire)
Aug-14-23 04:05PM	Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.60%
Aug-02-23 04:30PM	Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023 (GlobeNewswire) -5.26%
Aug-01-23 07:05AM	Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023 (GlobeNewswire)
Jul-31-23 07:05AM	Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting (GlobeNewswire)
Jul-20-23 07:05AM	Clearside Biomedicals Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings (GlobeNewswire)
Jul-11-23 04:05PM	Clearside Biomedical CEO George Lasezkay to Present at the SHARE Series Investor Event on Monday, July 17, 2023 (GlobeNewswire)
Jul-10-23 07:05AM	Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema (GlobeNewswire)
Jun-29-23 09:50AM	We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate (Simply Wall St.)
Jun-01-23 07:05AM	Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD (GlobeNewswire)
May-11-23 08:25AM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.90%
07:05AM	Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 04:30PM	Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference (GlobeNewswire) +7.41%
May-02-23 07:05AM	Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023 (GlobeNewswire)
Apr-27-23 07:05AM	Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting (GlobeNewswire)
Apr-18-23 07:05AM	Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD (GlobeNewswire)
Apr-12-23 07:05AM	Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -10.48%
Apr-09-23 09:42AM	Clearside Biomedical (NASDAQ:CLSD) adds US$12m to market cap in the past 7 days, though investors from five years ago are still down 88% (Simply Wall St.)
Apr-05-23 07:05AM	Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians (GlobeNewswire) -8.89%
Mar-11-23 03:14AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 06:35PM	Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.24%
04:05PM	Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-23-23 07:05AM	Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023 (GlobeNewswire) -5.26%
Feb-21-23 07:05AM	Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings (GlobeNewswire)
Feb-07-23 07:05AM	Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023 (GlobeNewswire)
Feb-06-23 07:30AM	Clearside Biomedical Announces Leadership Team Update (GlobeNewswire)
Feb-02-23 01:18PM	Clearside Biomedical Touts Encouraging Durable Data From Investigational Candidate For Vision Disorder (Benzinga)
07:05AM	Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD (GlobeNewswire)
Dec-22-22 09:52AM	2 Strong Buy Penny Stocks That Could Go Boom (TipRanks) +8.00%
05:05AM	Companies Like Clearside Biomedical (NASDAQ:CLSD) Can Afford To Invest In Growth (Simply Wall St.)
Nov-22-22 07:05AM	Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022 (GlobeNewswire)
Nov-11-22 05:26AM	Clearside Biomedical Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 01:24PM	Analyst Bumps Up Clearside Biomedical Target Price After Encouraging Trial Data (Benzinga)
07:05AM	Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference (GlobeNewswire)
Nov-09-22 09:05AM	Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.57%
07:15AM	Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
07:05AM	Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients (GlobeNewswire)
Nov-08-22 04:05PM	Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 07:05AM	Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022 (GlobeNewswire) +11.57%
Oct-31-22 08:52AM	Investors in Clearside Biomedical (NASDAQ:CLSD) have unfortunately lost 84% over the last five years (Simply Wall St.)
Oct-17-22 11:27AM	Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock? (Zacks)
Oct-04-22 07:05AM	Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedicals Proprietary Suprachoroidal Space Platform (GlobeNewswire) +14.17%
Sep-27-22 07:05AM	Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting (GlobeNewswire)
Aug-25-22 07:05AM	Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022 (GlobeNewswire)
Aug-11-22 06:21AM	These Analysts Think Clearside Biomedical, Inc.'s (NASDAQ:CLSD) Sales Are Under Threat (Simply Wall St.)
Aug-09-22 08:35AM	Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:05AM	Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chong Ngai Hang Victor	Chief Medical Officer	Nov 01 '24	Buy	1.00	36,500	36,500	100,000	Nov 04 04:15 PM
Chong Ngai Hang Victor	Chief Medical Officer	Jun 24 '24	Buy	1.06	23,500	24,910	63,500	Jun 24 04:38 PM
YERXA BENJAMIN R	Director	May 15 '24	Buy	1.31	7,813	10,235	17,957	May 15 05:28 PM
Gibney Anthony S	Director	Apr 18 '24	Buy	1.30	93,290	121,277	100,000	Apr 19 09:45 AM
Gibney Anthony S	Director	Apr 17 '24	Buy	1.25	6,710	8,388	6,710	Apr 19 09:45 AM
Chong Ngai Hang Victor	CHIEF MEDICAL OFFICER	Mar 20 '24	Buy	1.60	30,000	48,000	30,000	Mar 20 04:30 PM
WHITMORE BRADFORD T	10% Owner	Feb 07 '24	Buy	1.35	444,444	599,999	4,495,034	Feb 09 01:00 PM
LASEZKAY GEORGE M	CEO	Jan 19 '24	Sale	1.27	18,000	22,860	466,577	Jan 19 06:26 PM
Deignan Charles A.	Chief Financial Officer	Jan 19 '24	Sale	1.28	12,900	16,512	384,662	Jan 19 06:25 PM

BCRX

Biocryst Pharmaceuticals Inc

CLSD

Clearside Biomedical Inc

Upgrade your FINVIZ experience